1

Sarepta Therapeutics

#1480

Rank

$11.64B

Marketcap

US United States

Country

Sarepta Therapeutics
Leadership team

Mr. Douglas S. Ingram Esq. (Pres, CEO & Director)

Mr. Ian Michael Estepan (Exec. VP & CFO)

Mr. William F. Ciambrone (Exec. VP of Technical Operations)

Products/ Services
Biotechnology, Genetics, Health Care, Therapeutics
Number of Employees
500 - 1000
Headquarters
Cambridge, Massachusetts, United States
Established
1980
Company Registration
SEC CIK number: 0000873303
Revenue
500M - 1B
Traded as
SRPT
Social Media
Overview
Location
Summary
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
History

Sarepta started in Corvallis, Oregon on January 1, 1980 and was originally named Antivirals Inc. After occupying several research laboratory spaces in Corvallis, the company opened a production laboratory in Corvallis in February 2002 and was renamed AVI BioPharma Inc. The company made headlines in 2003 when it announced work on treatments for severe acute respiratory syndrome and the West Nile virus. In July 2009, the company announced they would move their headquarters from Portland, Oregon, north to Bothell, Washington, near Seattle. At that time, the company led by president and CEO Leslie Hudson had 83 employees and quarterly revenues of $3.2 million. AVI had yet to turn a profit and had not yet developed any commercial products as of July 2009. The company lost $19.7 million in the second quarter of 2009, and then won an $11.5 million contract with the U.S. Department of Defense's Defense Threat Reduction Agency in October 2009. By this time, the company had completed its headquarters move to Bothell.In 2012, the company moved a second time, to Cambridge, Massachusetts. At the time, CEO Chris Garabedian indicated the move was motivated by the need to recruit expertise in rare diseases. The Corvallis laboratory facility was closed in 2016.

In February 2019, Sarepta acquired five gene therapy candidates for $165 million after one of them, MYO-101, produced results with a new gene therapy candidate for patients with Limb-Girdle muscular dystrophy; two months after receiving a single treatment, muscles from all three patients were producing the protein they couldn't make on their own.As of 2022, there are three FDA-approved Duchenne muscular dystrophy drugs in Sarepta Therapeutics' portfolio.

Mission
Our mission at Sarepta is to develop and deliver life-transforming treatments with the potential to redefine the standards of care for rare neuromuscular diseases.
Vision
Our vision is to create a world where no one is denied access to safe, effective treatments and cures for rare neuromuscular diseases.
Key Team

Dr. Louise R. Rodino-Klapac Ph.D. (Exec. VP, Chief Scientific Officer and Head of R&D)

Mr. Ryan E. Brown (Sr. VP, Gen. Counsel & Corp. Sec.)

Bilal Arif (Sr. VP of Strategy and Operations)

Mary Jenkins (Sr. Mang. of Investor Relations)

Ms. Alison Nasisi (Chief People Officer & VP)

Dr. Diane L. Berry (Sr. VP of Global Health Policy and Gov. & Patient Affairs)

Mr. Dallan Murray (Sr. VP & Chief Customer Officer)

Recognition and Awards
Sarepta Therapeutics has received numerous awards, including the 2019 Genome BC Advanced Therapies award, the 2020 Prix Galien USA Rare Disease Research Award, and the 2021 BIO Association of Global Biopharma Excellence Award.
References
Sarepta Therapeutics
Leadership team

Mr. Douglas S. Ingram Esq. (Pres, CEO & Director)

Mr. Ian Michael Estepan (Exec. VP & CFO)

Mr. William F. Ciambrone (Exec. VP of Technical Operations)

Products/ Services
Biotechnology, Genetics, Health Care, Therapeutics
Number of Employees
500 - 1000
Headquarters
Cambridge, Massachusetts, United States
Established
1980
Company Registration
SEC CIK number: 0000873303
Revenue
500M - 1B
Traded as
SRPT
Social Media